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Summary Pretreatment serum levels of neurone specific enolase (NSE) were measured in patients with small
cell lung cancer (SCLC). Median values were significantly higher in patients with extensive compared with
limited stage disease (48 ng ml-' v. 17 ng ml-': P <0.001). Serial NSE levels paralleled the clinical response to
treatment. In 37 patients with limited SCLC, receiving identical chemotherapy, the pretreatment NSE level was
of prognostic significance: with an approximate reduction in median survival of 10% for each 5 ng ml'
incremental rise in NSE (P = 0.004).
Neural and neuroendocrine cells have the capacity to syn-
thesise the neurone-specific form of the glycolytic enzyme,
enolase (NSE). In several instances tumours derived from
these cells retain the ability to secrete NSE and it has been
suggested that the isoenzyme may be a useful tumour marker
in these circumstances.
Small cell lung cancer (SCLC) is the most common
neuroendocrine tumour. Several groups have shown that
serum NSE is elevated in the majority of patients with exten-
sive SCLC and a significant proportion of those with limited
disease (Carney et al., 1982; Johnson et al., 1984; Akoun et
al., 1985; Cooper et al., 1985; Esscher et al., 1985). Despite
reports that NSE levels are consistently higher in extensive
than limited stage SCLC, data on the prognostic value of
NSE are limited (Akoun et al., 1985; J0rgensen et al., 1988).
The present study was initiated in 1985 to determine the
utility of NSE as a tumour marker in SCLC, and to assess its
contribution as a prognostic indicator.
Patients and methods
At the time of diagnosis, serum samples from patients with
SCLC were stored at - 20°C; overtly haemolysed samples
were discarded as haemolysis may result in falsely elevated
NSE levels (Esscher et al., 1985). Assays were performed in
duplicate using the Pharmacia radioimmunoassay, with a
detection limit of 2.6 ng ml' and a suggested upper limit to
the normal range of 12.5 ngml-'.
Staging of SCLC was based on clinical examination, chest
radiology, liver ultrasound, transaminase and alkaline phos-
phatase levels, with other investigations (skeletal radiology,
bone or brain scans) undertaken if clinically indicated.
Limited stage SCLC was defined according to the criteria of
the Veterans Administration Lung Cancer Study Group
(Zelen, 1973) as tumour confined to one hemithorax, with or
without ipsilateral mediastinal or supraclavicular node
involvement. Metastasis outwith the specified nodal areas
was classified as extensive disease. As several multivariate
analyses have shown that the prognosis in SCLC is more
closely related to a few biochemical parameters and pertor-
mance status, than disease extent, these prognostic groups
based on albumin, sodium, alkaline phosphatase and alanine
transaminase have been included for patients in the survival
analyses.
The majority of patients (49 of 66) entered the West of
Scotland Lung Cancer Group randomised trial of four
courses of combination chemotherapy given at 3-weekly
intervals with or without verapamil 120 mg (6-hourly, orally,
for 5 days starting 48 h before each course). Chemotherapy
comprised intravenous cyclophosphamide 750 mg m-2,
adriamycin 40 mgm2 and vincristine 1.4 mgm-2 on day 1
with etoposide 75 mg m-2 on days 1, 2 and 3 (CAVE).
Patients with limited disease achieving complete radiological
and bronchoscopic remission received mediastinal and pro-
phylactic cranial irradiation: 30Gy in 10 fractions over 14
days to each site. A further two patients received CAVE off
study and 11 were treated with alternative combinations.
Four patients were considered unfit for specific therapy.
The median follow-up is 12 months (range >7 to >31
months) and 15 patients are currently alive. There was one
early death to which chemotherapy may have contributed
and two sudden deaths in which a cardiac dysrrhythmia
seemed probable. One patient died from pancreatic cancer at
9 months, without evidence of relapsed SCLC. Survival has
been calculated from initiation of therapy and includes
analysis of death from all causes.
The relationship between pretreatment NSE and survival
was fitted using proportional hazards model (Cox, 1972). The
estimated median survival times for various NSE values were
obtained from this fitted model. The comparison of median
NSE values between patients with extensive and limited
disease was carried out using the Mann-Whitney U test.
Results
Pretreatment NSE levels are shown in Table I. The median
level is significantly higher in patients with extensive than
limited disease (P <0.001). Although 12.5 ng ml' is
quoted as the upper limit of the normal range, it has been
suggested that 25 ng ml-' is the clinically relevant level
(Cooper et al., 1985; Esscher et al., 1985) and hence NSE
concentrations are shown separately for values between 12.5
and 25 ng ml-'. Most patients with limited disease have
levels in this range. The single patient with extensive SCLC
and NSE <12.5 ng ml-' had a cerebral metastasis as the
only extrathoracic disease. All six patients with NSE levels in
excess of 200 ng ml-' had large (>5 cm) liver metastases
and three had additional bone marrow disease.
Forty-six of 59 (76%) patients receiving chemotherapy
responded to treatment and in all those with intitially
elevated levels normalisation of NSE occurred, within 3
weeks in 77% of cases. NSE levels did not distinguish com-
plete (n = 21) from partial (n = 25) remission: median values
were 7 (range 5-10) and 8 (range 5-12) ng ml-' respectively.
Thirteen non-responding patients had minor reductions in
NSE levels though these never reached the quoted normal
range (< 12.5 ng ml-'). Of the remaining seven patients,
three died too early for response evaluation and four, all with
hepatic disease and including the three patients with the
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Table I Distribution of NSE levels in SCLC by stage by disease
NSE (ngml-') Percentage patients with NSE levels
Number Median Range < 12.5 ng mlh 12.5-25 ngml-' >25 ngml-'
Limited 42 17 (7-141) 29 48 21
Extensive 24 48 (9-710) 4 4 92
highest NSE levels (355, 490 and 710 ng ml-'), were con-
sidered unfit for specific therapy.
In 12 patients with pretreatment NSE >25 ng ml-', a rise
in NSE antedated clinical relapse by 3-12 weeks (median 6
weeks). One patient relapsing with brain and colonic metas-
tases had normal NSE levels at relapse though through
pretreatment these had been elevated.
Thirty-seven patients with limited stage SCLC were ran-
domised in the West of Scotland trial to receive CAVE with
or without verapamil. Their response and outcome, sub-
divided by pretreatment NSE levels, are shown in Table II.
The response rates are comparable among each of the sub-
groups, although the proportion of patients receiving
verapamil is lowest among those with the highest NSE.
Differences in time to progression and survival do not reach
statistically significant levels.
Pretreatment NSE levels for the same patients, subdivided
into prognostic groups based on performance status (0 or
1 = good), albumin (> 36 g 1' = good), alanine trans-
aminase (normal = good; Vincent et al., 1987), sodium
(> 136 mmol I- = good; Souhami et al., 1985) and alkaline
phosphatase (<1.5 x upper limit of normal = good;
Souhami et al., 1985) are shown in Table III. As LDH was
not routinely measured, the prognostic categories of Cerny et
al. (1987) could not be included. There was no difference
between NSE levels in the good and medium prognosis
groups.
However, when pretreatment NSE was plotted as a con-
tinuous variable against survival (Figure 1), a significant
association was seen (P = 0.004) with a reduction of approx-
imately 10% in median survival for each 5 ng ml-' incremen-
tal rise in NSE.
Discussion
Using the quoted, conventionally accepted, upper limit of the
normal NSE range of 12.5 ng ml-', 79% of our patients with
SCLC had raised levels. This proportion is comparable to the
observations of several other authors (Carney et al., 1982;
Johnson et al., 1984; Akoun et al., 1985; Cooper et al., 1985;
Esscher et al., 1985). However, a higher threshold of
25 ng ml-' has been suggested to give optimal specificity for
extensive SCLC (Cooper et al., 1985; Esscher et al., 1985)
and our data (Table I) would support this. Most patients
with limited SCLC had levels between 12.5 and 25ngml1l
and thus, if a level of 25 ng ml' were advocated for
serological screening, these patients would be missed.
The potential utility of NSE for monitoring patients with
SCLC has been documented (Carney et al., 1982; Johnson et
al., 1984; Akoun et al., 1985; Cooper et al., 1985; Esscher et
al., 1985). However, NSE concentrations do not appear
sufficiently sensitive to discriminate complete from partial
remission (Splinter et al., 1987). Furthermore, although
relapse is frequently preceded by rising NSE levels there is, as
yet, no evidence that early treatment of relapsed disease
prolongs survival. However, if salvage chemotherapy was
shown to be of value, the earlier detection of relapse by
rising NSE levels would enable treatment to be instituted
when the tumour burden was lower and chemotherapy
therefore more likely to be effective.
NSE levels are notably higher in extensive than limited
stage disease (Carney et al., 1982; Johnson et al., 1984;
Akoun et al., 1985; Cooper et al., 1985; Esscher et al., 1985),
and our results confirm this. The inferior prognosis of exten-
sive SCLC is well documented (Akoun et al., 1985; 0sterlind
et al., 1987; Vincent et al., 1987; Cerny et al., 1987), and in
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Figure 1 Relationship between pretreatment NSE concentration
and median survival in limited stage SCLC. 0, alive; V, dead;
estimated median survival.
Table II Responseand outcomeforpatientsrandomised in theWestofScotlandTrial of
CAVE ± verapamil, in relation to pretreatment NSE level
Median time Median
NSE Patient Number ± Response to progression survival
level number verapamil CR + PR/NR (months) (months)
< 12.5 ngml-' 12 6/6 8/4 15 18
12.5-25 ngml' 17 10/7 14/3 8 12
>25ngml-' 8 1/7 6/2 9 10
Table III Pretreatment NSE level and survival according to prognostic category
NSE level Survival in months
Prognostic category Patient number Median Range Median Range
Vincent et al. (1987)
Good 30 18 7-57 12 1-30
Medium 7 12 8-58 10 2-31 +
Souhami et al. (1985)
Good 27 17 7-57 13 5-30
Medium 10 17 8-58 8 1-31 +
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two series LDH levels constituted an independent prognostic
variable (Osterlind et al., 1987; Cerny et al., 1987). Further-
more, there is an association between serum concentrations
of NSE and LDH (J0rgensen et al., 1988), possibly indicative
of tumour bulk or liver metastases.
Data on the prognostic significance of NSE are limited.
Pretreatment NSE levels were not found to influence survival
in either limited or extensive disease in one series, although
numbers were small and the discriminant value used was the
upper limit of normal (Akoun et al., 1985). However, NSE
concentration and performance status appeared to be the
most sensitive prognostic factors in mulitvariate analysis of a
patient population including both limited and extensive
disease, although stratification for disease extent was neces-
sary as proportional death hazards were unequal in the two
groups (J0rgensen et al., 1988).
Our survival results are reported for limited disease SCLC
only because some patients with extensive disease received no
specific (n = 4) or possibly suboptimal treatment (n = 11) as a
consequence of poor performance status: both of these fac-
tors are likely to have compromised their survival. Our stag-
ing investigations should exclude from the limited disease
category patients with liver or bone metastases: those with
bone marrow infiltration may have been erroneously
included. However, marrow disease is associated with trans-
aminase elevation (Tritz et al., 1989) and such patients would
have been classified as having extensive stage on this basis.
Survival data are restricted to patients randomised in the
West of Scotland Lung Cancer trial who received identical
chemotherapy. This indicates that in patients with limited
SCLC there is a significant association between pretreatment
NSE and prognosis in that for each 5 ng ml' increase in
NSE, median survival is reduced by approximately 10%.
Although patient numbers are small, it is clear that the
majority of patients with limited stage SCLC fall into the
best prognostic group of Vincent et al. (1987) and Souhami
et al. (1985), and that NSE levels do not differ significantly
between the good and medium categories (Table III). It is
possible therefore that initial NSE level may be independent
of the currently accepted prognostic factors.
Clearly, data from more patients are necessary and must
be subjected to multivariate analysis to confirm that NSE
levels constitute an independent prognostic variable in small
cell lung cancer. However, the prospect of further refining the
prognostic indices in this disease is encouraging.
The authors are gateful to the Cancer Research Campaign for sup-
port of the Clinical Trials Unit and Mrs Marion McLeod for typing
the manuscript.
References
AKOUN, G.M., SCARNA, H.M., MILLERON, B.J., BENICHOU, M.P. &
HERMAN, D.P. (1985). Serum neuron-specific enolase. A marker
for disease extent and response to therapy for small-cell lung
cancer. Chest, 87, 39.
CARNEY, D.N., MARANGOS, P.J., IHDE, D.C. & 4 others (1982).
Serum neuron-specific enolase: a marker for disease extent and
response to therapy of small-cell lung cancer. Lancet, i, 583.
CERNY, T., BLAIR, V., ANDERSON, H., BRAMWELL, V. & THAT-
CHER, N. (1987). Pretreatment prognostic factors and scoring
system in 407 small-cell lung cancer patients. Int. J. Cancer, 39,
146.
COOPER, E.H., SPLINTER, T.A.W., BROWN, D.A., MUERS, M.F.,
PEAKE, M.D. & PEARSON, S.L. (1985). Evaluation of a
radioimunoassay for neuron specific enolase in small cell lung
cancer. Br. J. Cancer, 52, 333.
COX, D.R. (1972). Regression models and life tables (with discus-
sion). J. R. Stat. Soc. B, 34, 187.
ESSCHER, T., STEINHOLTZ, L., BERGH, J., NOU, E., NILSSON, K. &
PAHLMAN, S. (1985). Neurone specific enolase: a useful diagnos-
tic serum marker for small cell carcinoma of the lung. Thorax,
40, 85.
JOHNSON, D.H., MARANGOS, P.J., FORBES, J.T. & 4 others (1984).
Potential utility of serum neuron-specific enolase levels in small
cell carcinoma of the lung. Cancer Res., 44, 5409.
J0RGENSEN, L.G.M., OSTERLIND, K., HANSEN, H.H. & COOPER,
E.H. (1988). The prognostic influence of serum neuron specific
enolase in small cell lung cancer. Br. J. Cancer, 58, 805.
0STERLIND, K., HANSEN, H.H., HANSEN, M., DOMBERNOWSKY, P.
& ANDERSEN, P.K. (1986). Long-term disease-free survival in
small cell carcinoma of the lung: a study of clinical determinants.
J. Clin. Oncol., 4, 1307.
SOUHAMI, R.L., BRADBURY, I., GEDDES, D.M., SPIRO, S.G.,
HARPER, P.G. & TOBIAS, J.S. (1985). Prognostic significance of
laboratory parameters measured at diagnosis in small cell car-
cinoma of the lung. Cancer Res., 45, 2878.
SPLINTER, T.A.W., COOPER, E.H., KHO, G.S., OOSTEROM, R. &
PEAKE, M.D. (1987). Neuron-specific enolase as a guide to the
treatment of small cell lung cancer. Eur. J. Cancer Clin. Oncol.,
23, 171.
TRITZ, D.B., DOLL, D.C., RINGENBERG, S. & 4 others (1989). Bone
marow involvement in small cell lung cancer. Cancer, 63, 763.
VINCENT, M.D., ASHLEY, S.E. & SMITH, I.E. (1987). Prognostic fac-
tors in small cell lung cancer: A simple prognostic index is better
than conventional staging. Eur. J. Cancer Clin. Oncol., 23, 1589.
ZELEN, M. (1973). Keynote address on biostatistics and data re-
trieval. Cancer Chemother. Rep., 4, 31.